$ARTV

Banerjee Subhashis sold $5K of ARTV

Banerjee Subhashis (Chief Medical Officer) sold 429 shares of Artiva Biotherapeutics, Inc. (ARTV) at $12.00 on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Banerjee Subhashis
Published Aug 20, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market impact.

02

Market read

Low relevance; typical insider transaction with minimal price effect.

03

What to watch

Potential upcoming clinical data releases could change relevance of insider activity.

Relevance 2/10Novelty 4/10Timing: post-filing 2026-08-19

Background

Artiva Biotherapeutics filed a Form 4 reporting a $5K sale by its CMO under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

Form 4 disclosed Chief Medical Officer Banerjee Subhashis sold 429 shares for $5,148 via a 10b5-1 plan.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale size is small relative to total holdings and market cap; typical for 10b5-1 plans.

Market effects

None; biotech sector not affected by a small insider transaction.

None; transaction is company‑specific.

None

Counterpoint

Even small insider sales can signal concerns; monitor upcoming disclosures.

Key entities

  • Artiva Biotherapeutics, Inc.

    Biotech firm developing therapies.

  • Banerjee Subhashis

    Chief Medical Officer of Artiva.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARTVMed

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a